Article Text

Download PDFPDF
Review: intranasal mupirocin ointment reduces Staphylococcus aureus infections in nasal carriers

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.


Does mupirocin nasal ointment reduce Staphylococcus aureus infections in patients who are nasal carriers of S aureus?


Included studies compared intranasal mupirocin ointment with placebo, no treatment, or an alternative topical treatment in hospital inpatients or outpatients who were nasal carriers of microbiologically confirmed S aureus. Outcomes included S aureus infection, infection caused by other micro-organisms, and mortality.


Cochrane Wounds Group Specialised Register, CENTRAL, Medline, CINAHL, EMBASE/Excerpta Medica (all to May 2008); System for Information on Grey Literature; Index to Theses (ASLIB Index); mRCT;; abstracts from major scientific meetings (1995–2007); and reference lists were searched for published and unpublished randomised controlled trials (RCTs). Researchers, the manufacturer of mupirocin, and …

View Full Text


  • Source of funding: no external funding.